AIP 105
Alternative Names: AIP-105Latest Information Update: 28 Aug 2023
At a glance
- Originator Advanced Innovative Partners
- Class Imaging agents; Radiopharmaceutical diagnostics
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Rhabdomyosarcoma
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for clinical-Phase-Unknown development in Rhabdomyosarcoma(Diagnosis) in USA
- 23 Jul 2020 AIP 105 is available for licensing as of 23 Jul 2020 (https://www.advancedinnovativepartners.com/our-company)
- 21 Jul 2020 Clinical trials in Rhabdomyosarcoma (Diagnosis) in USA (unspecified route) (Advanced Innovative Partners website, July 2020)